<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4134">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581200</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00106306</org_study_id>
    <secondary_id>3U01AT009974-03S1</secondary_id>
    <nct_id>NCT04581200</nct_id>
  </id_info>
  <brief_title>Lift Mobile Mindfulness for COVID-19 Distress Symptoms</brief_title>
  <acronym>LIFTCOVID</acronym>
  <official_title>Addressing Psychological Distress Symptoms Among Serious Illness Survivors of a Viral Pandemic With a Completely Self-directed, Symptom-responsive Mobile Mindfulness Intervention: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial (RCT) nested within the NIH PETAL Network's COVID cohort&#xD;
      study (BLUE CORAL [Biology and Longitudinal Epidemiology: COVID Observational Study]) of&#xD;
      patients hospitalized for COVID-19-related illness. COVID-19 patients enrolled in BLUE CORAL&#xD;
      with elevated distress symptoms 1 month post-discharge will be randomized to either the Lift&#xD;
      mobile app intervention or a usual care control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The novel coronavirus (COVID-19) pandemic has changed access to and the delivery of medical&#xD;
      care across the world rapidly and radically as increasingly large waves of patients fill&#xD;
      clinics, hospital wards, and intensive care units (ICUs). Patients with comparable illnesses&#xD;
      have high rates of persistent psychological distress symptoms including depression, anxiety,&#xD;
      and PTSD. Currently there are few easily accessible therapies available for this distress in&#xD;
      this time of deep fear and worry, social distancing, cancelled clinics, isolation and&#xD;
      quarantine practices, and understaffed hospitals.&#xD;
&#xD;
      Lift, a novel mobile app-based mindfulness intervention, may be able to address COVID-19&#xD;
      patients' distress and access to care issues. Lift was piloted successfully in the intensive&#xD;
      care unit (ICU; R34 AT00819) and is currently in the midst of a multicenter factorial&#xD;
      experimental clinical trial designed to determine which of 8 versions is optimized for&#xD;
      symptom relief, cost, and scalability (parent U01 AT009974).&#xD;
&#xD;
      This 2-arm, parallel group randomized clinical trial seeks to expand the scope of the parent&#xD;
      U01 project to test the clinical impact of a psychological distress intervention rapidly&#xD;
      deployed during a pandemic. This trial will include 300 patients who were hospitalized due to&#xD;
      COVID-19; collect data at 1, 3, and 6 months post-discharge; and address 3 specific aims: (1)&#xD;
      Compare the clinical impact of Lift vs. usual care control and (2) Compare long-term&#xD;
      (6-month) outcomes of RCT patients both by treatment arm as well to the entire BLUE CORAL&#xD;
      cohort, and (3) Explore participant-reported barriers and facilitators to intervention&#xD;
      deployment, uptake, and engagement in a pandemic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor will be blinded to group assignment, as will the investigators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Patient Health Questionnaire-9 Item scale (PHQ-9)</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T2 (2 months post-randomization [i.e., 3 months post-hospital discharge)</time_frame>
    <description>Depression symptoms. Scores range from 0 (better) to 27 (worse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Health Questionnaire-9 Item scale (PHQ-9)</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T3 (5 months post-randomization [i.e., 6 months post-hospital discharge)</time_frame>
    <description>Depression symptoms. Scores range from 0 (better) to 27 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Generalized Anxiety Disorder 7-item scale (GAD-7)</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T2 (2 months post-randomization [i.e., 3 months post-hospital discharge)</time_frame>
    <description>Anxiety symptoms. Scores range from 0 (better) to 21 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Generalized Anxiety Disorder 7-item scale (GAD-7)</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T3 (5 months post-randomization [i.e., 6 months post-hospital discharge)</time_frame>
    <description>Anxiety symptoms. Scores range from 0 (better) to 21 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQOL-5DL scale</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T2 (2 months post-randomization [i.e., 3 months post-hospital discharge)</time_frame>
    <description>Quality of life instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQOL-5DL scale</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T3 (5 months post-randomization [i.e., 6 months post-hospital discharge)</time_frame>
    <description>Quality of life instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary symptoms</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T2 (2 months post-randomization [i.e., 3 months post-hospital discharge)</time_frame>
    <description>Cardiopulmonary symptoms such as breathlessness, fatigue, oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary symptoms</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T3 (5 months post-randomization [i.e., 6 months post-hospital discharge)</time_frame>
    <description>Cardiopulmonary symptoms such as breathlessness, fatigue, oxygen use</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Healthcare utilization</measure>
    <time_frame>T1 (time of randomization [i.e., 1 month post-hospital discharge), T2 (2 months post-randomization [i.e., 3 months post-hospital discharge), T3 (5 months post-randomization [i.e., 6 months post-hospital discharge)</time_frame>
    <description>Hospital readmissions and clinic visits during follow up</description>
  </other_outcome>
  <other_outcome>
    <measure>Intervention adherence</measure>
    <time_frame>T2 (2 months post-randomization [i.e., 3 months post-hospital discharge), T3 (5 months post-randomization [i.e., 6 months post-hospital discharge)</time_frame>
    <description>Quantified by number of intervention sessions, weekly surveys, and intervention elements (e.g., videos, audio) completed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <condition>Cardiorespiratory Failure</condition>
  <arm_group>
    <arm_group_label>Lift mobile mindfulness program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive standard dose Lift mobile mindfulness program intervention content, app-based response to elevated symptoms, and no introductory call from a therapist. This program lasts 1 month and includes 4 unique weeks' worth of audio, video, and text content.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lift</intervention_name>
    <description>The intervention is a mobile app-based mindfulness training program designed to be used over a 1-month period.</description>
    <arm_group_label>Lift mobile mindfulness program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        BLUE CORAL eligibility (the parent cohort study from which RCT participants will be&#xD;
        recruited)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Adult hospitalized within 14 days of a positive PCR test for COVID-19&#xD;
&#xD;
          2. Evidence of acute COVID-19, with fever or respiratory manifestations, as characterized&#xD;
             by signs and symptoms such as cough, dyspnea, tachypnea, hypoxemia, and infiltrates on&#xD;
             chest imaging.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Lack of informed consent&#xD;
&#xD;
          2. More than 72 hours of continuous hospitalization.&#xD;
&#xD;
          3. Comfort care orders in place at the time of enrollment and/or unexpected to survive&#xD;
             for 24 hours&#xD;
&#xD;
          4. Prisoners&#xD;
&#xD;
          5. Previous enrollment in BLUE CORAL&#xD;
&#xD;
        LIFT COVID RCT eligibility&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Enrolled in BLUE CORAL&#xD;
&#xD;
          2. Survival to time of BLUE CORAL 1-month post-discharge interview&#xD;
&#xD;
        2. English-speaking 3. Domiciled with access to a working telephone and smartphone, tablet,&#xD;
        or computer with wifi or internet connection 4. Absence of severe dementia or cognitive&#xD;
        dysfunction either before hospitalization or at time of 1 month post-discharge interview&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. PHQ-9 &lt;5 at time of interview 1 month post-discharge&#xD;
&#xD;
          2. Suicidal ideation at time of interview 1 month post-discharge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher E Cox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher E Cox, MD</last_name>
    <phone>9196817232</phone>
    <email>Christopher.cox@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allie Frear</last_name>
    <phone>9196848914</phone>
    <email>allie.frear@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado - Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey McKeehan</last_name>
      <phone>303-724-6080</phone>
      <email>jeffrey.mckeehan@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Kamphuis, MPH</last_name>
      <email>Lee.Kamphuis@va.gov</email>
    </contact>
    <investigator>
      <last_name>Theodore Iwashyna, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allie Frear</last_name>
      <phone>919-684-8914</phone>
      <email>allie.frear@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Cox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madeleine McDougal</last_name>
      <email>mcdoumad@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine L Hough, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://lift.duke.edu/covid</url>
    <description>Study website</description>
  </link>
  <reference>
    <citation>Cox CE, Porter LS, Buck PJ, Hoffa M, Jones D, Walton B, Hough CL, Greeson JM. Development and preliminary evaluation of a telephone-based mindfulness training intervention for survivors of critical illness. Ann Am Thorac Soc. 2014 Feb;11(2):173-81. doi: 10.1513/AnnalsATS.201308-283OC.</citation>
    <PMID>24303911</PMID>
  </reference>
  <reference>
    <citation>Cox CE, Hough CL, Jones DM, Ungar A, Reagan W, Key MD, Gremore T, Olsen MK, Sanders L, Greeson JM, Porter LS. Effects of mindfulness training programmes delivered by a self-directed mobile app and by telephone compared with an education programme for survivors of critical illness: a pilot randomised clinical trial. Thorax. 2019 Jan;74(1):33-42. doi: 10.1136/thoraxjnl-2017-211264. Epub 2018 May 23.</citation>
    <PMID>29793970</PMID>
  </reference>
  <reference>
    <citation>Cox CE, Olsen MK, Gallis JA, Porter LS, Greeson JM, Gremore T, Frear A, Ungar A, McKeehan J, McDowell B, McDaniel H, Moss M, Hough CL. Optimizing a self-directed mobile mindfulness intervention for improving cardiorespiratory failure survivors' psychological distress (LIFT2): Design and rationale of a randomized factorial experimental clinical trial. Contemp Clin Trials. 2020 Sep;96:106119. doi: 10.1016/j.cct.2020.106119. Epub 2020 Aug 15.</citation>
    <PMID>32805434</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>critical illness</keyword>
  <keyword>psychological distress</keyword>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <keyword>adults</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will follow NIH/NCCIH guidelines for data access.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>We will follow NIH guidelines.</ipd_time_frame>
    <ipd_access_criteria>We will follow NIH and institutional guidelines.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

